Tag: transactions

WASHINGTON, D.C., July 10, 2025 (GLOBE NEWSWIRE) -- via IBN – On Thursday, July 10, 2025, Dickinson Wright filed a lawsuit on behalf of the law firm’s client, Datavault AI, Inc. (Nasdaq: DVLT), (Datavault AI), alleging securities fraud (stock manipulation), defamation and intentional tort against “John Doe” “naked” short sellers of Datavault AI common stock on the Nasdaq Stock Market. The Complaint alleges that the short sellers engaged in the unlawful practice of “naked short selling” and other manipulative devices – including marking the close, painting the tape, spoofing and layering. The Complaint further alleges that the “John Does” for themselves or acting in concert with the “naked” short sellers also published materially false and misleading and defamatory information on internet chat room “Stocktwits” and on LinkedIn. The lawsuit, filed in federal court in Chicago, seeks unspecified compensatory and special damages and other relief.

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AlphaGen Intelligence Corp. (CSE: AIC | OTC: APETF | FSE: W4V) (“AlphaGen'' or the “Company”) announces, further to its news release dated July 3, 2025, that it has issued 2,251,326 common shares in the capital of the Company (each, a “Share”), at a deemed price of $0.1463 per Share in settlement of outstanding debts owed to certain creditors of the Company, including Eli Dusenbury (a director and the CFO of the Company) in the amount of $329,369.58 (the “Debt Settlement”).

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces the extension of its long-term strategic partnership with Boyd Gaming Corporation (“Boyd”) to 2038 and the buyout of Boyd’s 5% stake in FanDuel Group (“FanDuel”), together “the Agreement”.

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.

In Partnership with the California New Car Dealers Association (CNCDA), DCG to Host Private Gathering for Industry Leaders During Monterey Car Week

Not for distribution to United States newswire services or for dissemination in the United States

ICG Enterprise Trust plc (the “Company”)